AU2002313628A1 - Tamper resistant oral dosage form - Google Patents
Tamper resistant oral dosage formInfo
- Publication number
- AU2002313628A1 AU2002313628A1 AU2002313628A AU2002313628A AU2002313628A1 AU 2002313628 A1 AU2002313628 A1 AU 2002313628A1 AU 2002313628 A AU2002313628 A AU 2002313628A AU 2002313628 A AU2002313628 A AU 2002313628A AU 2002313628 A1 AU2002313628 A1 AU 2002313628A1
- Authority
- AU
- Australia
- Prior art keywords
- dosage form
- oral dosage
- tamper resistant
- resistant oral
- tamper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000006186 oral dosage form Substances 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29260301P | 2001-05-22 | 2001-05-22 | |
| US60/292,603 | 2001-05-22 | ||
| PCT/US2002/016269 WO2002094173A2 (en) | 2001-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002313628A1 true AU2002313628A1 (en) | 2002-12-03 |
Family
ID=23125385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002313628A Abandoned AU2002313628A1 (en) | 2001-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1395224A4 (en) |
| AU (1) | AU2002313628A1 (en) |
| WO (1) | WO2002094173A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| ES2371462T3 (en) * | 2003-01-13 | 2012-01-03 | Shire Llc | CONJUGATES OF CARBOHYDRATES TO PREVENT THE ABUSE OF CONTROLLED SUBSTANCES. |
| NZ542969A (en) | 2003-04-30 | 2009-09-25 | Purdue Pharma Lp | Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
| US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU682192B2 (en) * | 1993-06-30 | 1997-09-25 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
| US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
| US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
-
2002
- 2002-05-22 AU AU2002313628A patent/AU2002313628A1/en not_active Abandoned
- 2002-05-22 WO PCT/US2002/016269 patent/WO2002094173A2/en not_active Ceased
- 2002-05-22 EP EP02753331A patent/EP1395224A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1395224A4 (en) | 2005-10-26 |
| WO2002094173A3 (en) | 2003-02-20 |
| WO2002094173A2 (en) | 2002-11-28 |
| EP1395224A2 (en) | 2004-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002301259A1 (en) | Simethicone solid oral dosage form | |
| GB0117618D0 (en) | Pharmaceutical dosage form | |
| ZA200207755B (en) | Simethicone solid oral dosage form. | |
| PL364621A1 (en) | Nicotine-containing oral dosage form | |
| HUP0203204A3 (en) | Oral dosage forms | |
| GB0117619D0 (en) | Pharmaceutical dosage form | |
| GB0104534D0 (en) | Pharmaceutical combination | |
| GB2383989B (en) | Improved oral medicine dispenser | |
| HUP0400850A3 (en) | Oral pharmaceutical compositions | |
| IL161143A0 (en) | A flash-melt pharmaceutical oral dosage composition | |
| GB0124523D0 (en) | Pharmaceutical combination | |
| AU2002313628A1 (en) | Tamper resistant oral dosage form | |
| HUP0401599A3 (en) | Extended release oral dosage form | |
| GB0129270D0 (en) | Pharmaceutical combination | |
| EP1357898A4 (en) | Improved controlled release oral dosage form | |
| GB0129397D0 (en) | Pharmaceutical combination | |
| AU2003299739A1 (en) | Tamper resistant package | |
| GB0129872D0 (en) | Novel pharmaceutical | |
| GB0129395D0 (en) | Pharmaceutical combination | |
| AU2002342940A1 (en) | New pharmaceutical compounds | |
| ZA200401085B (en) | A new extended release oral dosage form. | |
| AU2002330285A1 (en) | Triclosan dosage form | |
| GB0130510D0 (en) | Novel pharmaceutical | |
| GB0130511D0 (en) | Novel pharmaceutical | |
| GB0130509D0 (en) | Novel pharmaceutical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |